You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Triweekly Cetuximab

Showing 1 - 25 of 829
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023

Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Recruiting
  • Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
  • Banqiao, New Taipei, Taiwan
    Department of Obstetrics and Gynecology, Far Eastern Memorial Ho
Jan 1, 2023

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Ovarian Cancer Trial in Milwaukee (Pembrolizumab, Carboplatin, Paclitaxel)

Active, not recruiting
  • Ovarian Cancer
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Apr 7, 2022

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial in Worldwide (palbociclib, Cetuximab, Placebo)

Completed
Has Results
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • La Jolla, California
  • +70 more
Oct 10, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

Advance NSCLC Trial (GFH925, Cetuximab)

Not yet recruiting
  • Advance Non-small Cell Lung Cancer
  • (no location specified)
Mar 7, 2023

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Trial in Guangzhou (Cetuximab, Zimberelimab, Docetaxel)

Not yet recruiting
  • Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Oct 24, 2023

Metastatic Colorectal Cancer Trial in Italy (Cetuximab, Avelumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Ancona, Italy
  • +23 more
Oct 25, 2022

Tumors Trial in Worldwide (Encorafenib, Cetuximab, Oxaliplatin)

Recruiting
  • Neoplasms
  • Phoenix, Arizona
  • +396 more
Jan 25, 2023

Glioblastoma, High-grade Glioma Trial in Groningen (Cetuximab-IRDye800)

Recruiting
  • Glioblastoma
  • High-grade Glioma
  • Groningen, Netherlands
    UMCG
Jun 26, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Monalizumab, Cetuximab)

Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Tucson, Arizona
  • +126 more
Oct 21, 2022

Colorectal Cancer Liver Metastases Trial in Shanghai (Cetuximab)

Not yet recruiting
  • Colorectal Cancer Liver Metastases
  • Shanghai, Shanghai, China
  • +1 more
May 22, 2023

Active, not recruiting
  • Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • +8 more
  • Cetuximab
  • +3 more
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute (UPCI)
Jan 26, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Lung Cancer, Video-assisted Thoracic Surgery, EGFR Trial in Torino (Cetuximab-IRDye800)

Not yet recruiting
  • Lung Cancer
  • +3 more
  • Torino, TO, Italy
    Azienda Ospedaliera Universitaria Città della Salute e della Sci
Oct 23, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity Trial in Guangzhou (Crisaborole Ointment, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    WeiWei Xiao
Nov 3, 2023

Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,

Not yet recruiting
  • Colon Adenocarcinoma
  • +4 more
  • (no location specified)
Jan 24, 2023

Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas Trial in Miami (SIACI of cetuximab and bevacizumab)

Not yet recruiting
  • Glioblastoma Multiforme
  • +4 more
  • SIACI of cetuximab and bevacizumab
  • Miami, Florida
    Jackson Memorial Hospital
Jul 14, 2023

Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head Neck Cancer Trial in United States (Lenvatinib

Completed
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Oct 13, 2022

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023